InterMune, Inc. (NASDAQ:ITMN)

CAPS Rating: 2 out of 5

The Company is a biotech company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

Recs

1
Player Avatar BlackshearFund (< 20) Submitted: 5/5/2010 7:30:47 PM : Outperform Start Price: $10.06 ITMN Score: -6.67

Oversold. Might see 15's again soon.

Report this Post Reply

Featured Broker Partners


Advertisement